Brigham and Women’s Faulkner Hospital Becomes the First in Massachusetts to Offer Innovative New Procedure to Treat Symptomatic Uterine Fibroids

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Brigham and Women’s Faulkner Hospital is the first provider in Massachusetts to offer the Sonata® System as a treatment for symptomatic uterine fibroids. Fibroids are benign growths in or around the uterus, with about 70 percent of white women and more than 80 percent of Black women having uterine fibroids before the age of 50. Uterine fibroids may cause significant and debilitating symptoms, including heavy menstrual bleeding. Symptoms may worsen over time if fibroids are left untreated, which leads to more than two million women in the U.S. undergoing treatment for uterine fibroids each year.

“Our goal at Brigham and Women’s Faulkner Hospital is to be able to offer our patients with symptomatic fibroids as many treatments options as possible so that we can match the appropriate patient to the appropriate intervention,” said James A. Greenberg, MD, Chief of Gynecology, Brigham and Women's Faulkner Hospital and Associate Professor, Harvard Medical School. “The introduction of transcervical RF myoma ablation is an exciting and essential addition to our toolkit. For the first time, the Sonata System allows us to provide women a completely incision-free procedure to treat single or multiple fibroids, with very fast recovery and excellent results. This is a huge leap forward for women who wish to preserve their uterus, avoid invasive surgery, and achieve long term reduction in heavy menstrual bleeding.”

The Sonata System uses a unique intrauterine ultrasound handpiece to locate and target the individual fibroids. Radiofrequency energy is delivered to shrink the fibroid and reduce symptoms. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes, and locations. The fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions to the abdomen, no tissue is surgically removed, and the uterus is preserved. Clinical studies demonstrate that nearly 90 percent of women showed a reduction in menstrual bleeding at three months and 95 percent with a reduction at 12 months. More than 50 percent of women return to normal activities the next day. Additionally, 94 percent of patients were satisfied at two and three years after the procedure.

“Dr. Greenberg has long been a pioneer in offering effective new treatments to women, and we are excited he and Brigham and Women's Faulkner Hospital are offering the Sonata Treatment for women with symptomatic fibroids. Invasive surgery can be a major deterrent to those who would otherwise seek treatment. The Sonata System offers an alternative to not only hysterectomy and myomectomy, but provides an option for those women that are not satisfied with their medical management or simply watchful waiting,” said Chris Owens, President and CEO of Gynesonics. “We look forward to hearing more from Dr. Greenberg and his patients about the life changing impact created by the Sonata Treatment.”

For more information on the Sonata Treatment and to watch patient testimonials, please visit www.sonatatreatment.com.

To make an appointment with Dr. Greenberg or a member of his team at Brigham Faulkner Ob/Gyn Associates, click here or call 617-983-7003.